Results of Annual General Meeting
Biodexa Pharmaceuticals (NASDAQ: BDRX), a clinical stage biopharmaceutical company, announced that all resolutions proposed at its Annual General Meeting held on June 26, 2025, were successfully passed by shareholders. The company, which focuses on developing innovative treatments for diseases with unmet medical needs, has made the full text of the passed resolutions available on its corporate website under the investor relations section.
Biodexa Pharmaceuticals (NASDAQ: BDRX), una società biofarmaceutica in fase clinica, ha annunciato che tutte le delibere proposte durante l'Assemblea Annuale degli Azionisti tenutasi il 26 giugno 2025 sono state approvate con successo dai soci. L'azienda, che si concentra nello sviluppo di trattamenti innovativi per malattie con bisogni medici insoddisfatti, ha reso disponibile il testo completo delle delibere approvate sul proprio sito web aziendale nella sezione relazioni con gli investitori.
Biodexa Pharmaceuticals (NASDAQ: BDRX), una compañía biofarmacéutica en etapa clínica, anunció que todas las resoluciones propuestas en su Asamblea General Anual celebrada el 26 de junio de 2025 fueron aprobadas exitosamente por los accionistas. La empresa, que se enfoca en desarrollar tratamientos innovadores para enfermedades con necesidades médicas no cubiertas, ha puesto a disposición el texto completo de las resoluciones aprobadas en su sitio web corporativo, en la sección de relaciones con inversores.
Biodexa Pharmaceuticals (NASDAQ: BDRX)는 임상 단계 바이오제약 회사로서 2025년 6월 26일에 개최된 연례 주주총회에서 제안된 모든 결의안이 주주들에 의해 성공적으로 통과되었다고 발표했습니다. 이 회사는 충족되지 않은 의료 수요가 있는 질병에 대한 혁신적인 치료법 개발에 주력하고 있으며, 통과된 결의안 전문을 투자자 관계 섹션의 회사 웹사이트에 공개했습니다.
Biodexa Pharmaceuticals (NASDAQ : BDRX), une société biopharmaceutique en phase clinique, a annoncé que toutes les résolutions proposées lors de son Assemblée Générale Annuelle tenue le 26 juin 2025 ont été adoptées avec succès par les actionnaires. L'entreprise, qui se concentre sur le développement de traitements innovants pour des maladies aux besoins médicaux non satisfaits, a mis à disposition le texte intégral des résolutions adoptées sur son site internet dans la section relations investisseurs.
Biodexa Pharmaceuticals (NASDAQ: BDRX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, gab bekannt, dass alle auf der Hauptversammlung am 26. Juni 2025 vorgeschlagenen Beschlüsse von den Aktionären erfolgreich angenommen wurden. Das Unternehmen, das sich auf die Entwicklung innovativer Behandlungen für Krankheiten mit ungedecktem medizinischem Bedarf spezialisiert hat, hat den vollständigen Text der angenommenen Beschlüsse im Bereich Investor Relations auf seiner Unternehmenswebsite veröffentlicht.
- None.
- None.
June 27, 2023
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Results of Annual General Meeting
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company’s shareholders were duly passed.
The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#agms.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer: tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
FAQ
What were the results of Biodexa Pharmaceuticals (BDRX) 2025 Annual General Meeting?
Where can investors find the full text of BDRX's AGM resolutions?
When did Biodexa Pharmaceuticals (BDRX) hold its 2025 Annual General Meeting?
What type of company is Biodexa Pharmaceuticals (BDRX)?
